DePuy Synthes, Pacira partner on Exparel education: 5 key notes

Pacira Pharmaceuticals partnered with DePuy Synthes Sales to market the company’s bupivacaine liposome injectable suspension Exparel for orthopedic surgeries in the United States.

Advertisement

Here are five key notes:

 

1. Under the agreement, DePuy Synthes field representatives will collaborate with and supplement the Pacira field teams with Exparel education in the hospital surgical suite and ASC.

 

2. Pacira will focus on soft tissue surgeons in addition to supporting DePuy Synthes’ efforts with joint reconstruction, spine, sports medicine and trauma surgeons.

 

3. Pacira will remain the overall Exparel account manager.

 

4. The collaboration expands Pacira’s marketing and educational activities as well as tailors their material to specific patient groups.

 

5. Pacira expects to report key Exparel data sets in orthopedic procedures this year.

 

More articles on orthopedic devices:
Zimmer Biomet, Implanet, Spinal Elements & more: 8 device company key notes
SpineFrontier improves MISquito Percutaneous Pedicle Screw System: 7 key points
Orthofix reports final resolution to SEC investigations: 6 insights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new product launches and leadership appointments, here are seven key headlines from Stryker in the first quarter of 2026.…

  • Xtant Medical’s 2025 revenue reached $133.9 million, a 14% increase year over year, according to financial results posted March 31.…

Advertisement

Comments are closed.